跳至主要内容
临床试验/NCT06454916
NCT06454916已完成不适用

GI Windows Flexagon Self Forming Magnet Anastomosis Plus OTOLoc for Creating Small Bowel Anastomoses in Patients Undergoing Surgical Procedures

GI Windows, Inc.14 个研究点 分布在 1 个国家目标入组 79 人开始时间: 2024年10月4日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
79
试验地点
14
主要终点
Number of Participants with Successful Anastomosis Creation without the Need for Reoperation

研究概览

简要总结

The primary objective of this trial is to investigate the safety and effectiveness of the Flexagon SFM system plus OTOLoc when used to create a small bowel anastomosis in subjects undergoing laparoscopic small bowel surgery.

详细描述

This is a multicenter, pivotal study in which clinical outcomes will be prospectively evaluated for a minimum of 70 subjects undergoing anastomosis creation using the Flexagon SFM system plus OTOLoc.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 22 years or older at screening
  • Candidate for laparoscopic small bowel surgery requiring small bowel anastomosis with cardiac/medical clearance for surgery
  • Able to understand and sign informed consent document
  • American Society of Anesthesiologists (ASA) score < IV at time of procedure
  • Lives, and intends to remain, within a 185-mile radius of study center for the duration of the study
  • Able to refrain from smoking during study follow-up period

排除标准

  • Known or suspected allergy to silicone, nickel, titanium or Nitinol
  • BMI > 55 kg/m2
  • Uncontrolled diabetes (defined as HbA1c >10%)
  • Congenital or acquired anomalies of the GI tract, including atresia or malrotation
  • Diagnosed with obstructed or perforated colon cancer
  • Any documented conditions for which endoscopy and/or laparoscopy would be contraindicated or history of previous technically difficult or failed endoscopy
  • Any previous major surgery on the stomach, duodenum, hepatobiliary tree (excluding laparoscopically removed gallbladder or prior sleeve gastrectomy), pancreas or right colon
  • Coagulation deficiency not normalized by medical treatment or platelet count <50,000/µL
  • Known moderate to severe renal disease (eGFR < 44 milliliters per minute per 1.73m2) or ongoing dialysis
  • Hyperkalemia / hypercoagulability or prior Venus Thromboembolism / Pulmonary Embolism
  • Immunocompromised (e.g., active treatment for malignancies, hematologic malignancy, on immunosuppressive therapy, moderate or severe primary immunodeficiency, advanced or untreated HIV, active treatment with high-dose corticosteroids (i.e., 20 or more mg of prednisone or equivalent per day when administered for 2 or more weeks prior to surgery) or other immunosuppressive or immunomodulatory agents
  • Active H. pylori infection
  • Active or suspected infection at the surgical site or a CDC Class 3/contaminated or Class 4/dirty-infected surgical wound.
  • Obstructive Sleep Apnea on CPAP unless assessed and cleared by independent physician
  • Contraindication to general anesthesia
  • Breast-feeding, pregnant, or planning on becoming pregnant during the follow-up period
  • Currently participating or has participated in another clinical trial within the past 30 days and is receiving/has received an investigational drug, device, or biologic agent
  • Subject is not appropriate for inclusion in the clinical trial, per the medical opinion of the Principal Investigator

结局指标

主要结局

Number of Participants with Successful Anastomosis Creation without the Need for Reoperation

时间窗: 30 Days

The study's primary endpoint (patient success) is defined as successful anastomosis created with the Flexagon SFM without placement procedure, device or target anastomosis-related reoperation through 30 days.

次要结局

未报告次要终点

研究者

发起方
GI Windows, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验